Farina Klocksieben

Mrs. Farina Klocksieben

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
TRTea Reljic
Tea Reljic
AKAmbuj Kumar
Ambuj Kumar
FKFarina Klocksieben
Farina Klocksieben
BDBenjamin Djulbegovic
Benjamin Djulbegovic
Objective: To assess the efficacy of active treatment targeted at underlying disease (TTD)/potentially curative treatments versus palliative care (PC) in improving overall survival (OS) in terminally ill patients. Design: We performed a systematic review and meta-analysis of randomised controlled trials (RCT). Methodological quality of included RCTs was assessed using the Cochrane risk of bias tool. Data sources: Medline and Cochrane databases were searched, with no language restriction, from inception to 19 October 2016. Eligibility criteria for selecting studies: Any RCT assessing the efficacy of any active TTD versus PC in adult patients with terminal illness with a prognosis of <6-month survival were eligible for inclusion. Results: Initial search identified 8252 citations of which 10 RCTs (15 comparisons, 1549 patients) met inclusion criteria. All RCTs included patients with cancer. OS was reported in 7 RCTs (8 comparisons, 1158 patients). The pooled results showed no statistically significant difference in OS between TTD and PC (HR (95% CI) 0.85 (0.71 to 1.02)). The heterogeneity between pooled studies was high (I 2 =62.1%). Overall rates of adverse events were higher in the TTD arm. Conclusions: Our systematic review of available RCTs in patients with terminal illness due to cancer shows that TTD compared with PC did not demonstrably impact OS and is associated with increased toxicity. The results provide assurance to physicians, patients and family that the patients' survival will not be compromised by referral to hospice with focus on PC.

4 September 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
MRMarianne Razavi
Marianne Razavi
PGPaul Glasziou
Paul Glasziou
FKFarina Klocksieben
Farina Klocksieben
JIJohn P. A. Ioannidis
John P. A. Ioannidis
ICIain Chalmers
Iain Chalmers
BDBenjamin Djulbegovic
Benjamin Djulbegovic
A well-designed randomized clinical trial (RCT) is widely considered the most reliable approach for evaluating the efficacy of clinical interventions or assessing the probable benefit of a medical device. However, RCTs often face practical limitations, such as difficulties in accruing patients, or other logistical or feasibility issues. As a result, alternative methods for the evaluation of treatments are increasingly considered, such as the assessment of a health interventions’ effects in nonrandomized, observational studies.1 Although such evaluations often provide results similar to those seen in RCTs,2,3 exceptions are not uncommon.4 The main concern about non-RCTs is that it is currently challenging to predict with confidence when the results of RCTs will be concordant with those of observational studies. The consequences of such a discordance can sometimes be disastrous.5,6

1 June 2018 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
BDBenjamin Djulbegovic
Benjamin Djulbegovic
PGPaul Glasziou
Paul Glasziou
FKFarina Klocksieben
Farina Klocksieben
TRTea Reljic
Tea Reljic
MVMagali VanDenBergh
Magali VanDenBergh
ICIain Chalmers
Iain Chalmers
The aim of this study was to evaluate how often the European Medicines Agency (EMA) has authorized drugs based on nonrandomized studies and whether there is an association between treatment effects and EMA preference for further testing in randomized clinical trials (RCTs). We reviewed all initial marketing authorizations in the EMA database on human medicines between 1995 and 2015 and included authorizations granted without randomized data. We extracted data on treatment effects and EMA preference for further testing in RCTs. Of 723 drugs, 51 were authorized based on nonrandomized data. These 51 drugs were licensed for 71 indications. In the 51 drug-indication pairs with no preference for further RCT testing, effect estimates were large [odds ratio (OR): 12.0 (95% confidence interval {CI}: 8.1-17.9)] compared to effect estimates in the 20 drug-indication pairs for which future RCTs were preferred [OR: 4.3 (95% CI 2.8-6.6)], with a significant difference between effects (P = 0.0005). Nonrandomized data were used for 7% of EMA drug approvals. Larger effect sizes were associated with greater likelihood of approval based on nonrandomized data alone. We did not find a clear treatment effect threshold for drug approval without RCT evidence.

1 August 2019 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MIMadiha Iqbal
Madiha Iqbal
TRTea Reljic
Tea Reljic
FKFarina Klocksieben
Farina Klocksieben
TSTaimur Sher
Taimur Sher
EAErnesto Ayala
Ernesto Ayala
MKMohamed A. Kharfan-Dabaja
Mohamed A. Kharfan-Dabaja
Human T cell lymphotropic virus type 1 (HTLV1)-associated adult T cell leukemia/lymphoma (ATLL) is an aggressive malignant disorder. Intensive conventional chemotherapy regimens and autologous hematopoietic cell transplantation (HCT) have failed to improve outcomes in ATLL. Allogeneic HCT (allo-HCT) is commonly offered as front-line consolidation despite lack of randomized controlled trials. We performed a comprehensive search of the medical literature using PubMed/Medline, EMBASE, and Cochrane reviews on September 10, 2018. We extracted data on clinical outcomes related to benefits (complete response [CR], overall survival [OS], and progression-free survival [PFS]) and harms (relapse and nonrelapse mortality [NRM]), independently by 2 authors. Our search strategy identified a total of 801 references. Nineteen studies (n = 2446 patients) were included in the systematic review; however, only 18 studies (n = 1767 patients) were included in the meta-analysis. Reduced intensity conditioning regimens were more commonly prescribed (52%). Bone marrow (50%) and peripheral blood (40%) were more frequently used as stem cell source. The pooled post-allografting CR, OS, and PFS rates were 73% (95% confidence interval [CI], 57% to 87%), 40% (95% CI, 33% to 46%), and 37% (95% CI, 27% to 48%), respectively. Pooled relapse and NRM rates were 36% (95% CI, 28% to 43%) and 29% (95% CI, 21% to 37%), respectively. The heterogeneity among the included studies was generally high. These results support the use of allo-HCT as an effective treatment for patients with ATLL, yielding pooled OS rates of 40%, but relapse still occurs in over one-third of cases. Future studies should evaluate strategies to help reduce relapse in patients with ATLL undergoing allo-HCT.

1 May 2021 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
WKWilliam N. Kelly
William N. Kelly
MHMei-Jen Ho
Mei-Jen Ho
KBKrystal Bullers
Krystal Bullers
FKFarina Klocksieben
Farina Klocksieben
AKAmbuj Kumar
Ambuj Kumar

1 February 2020 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
ESEthan Y. Song
Ethan Y. Song
PVPuja Venkat
Puja Venkat
MFMichael Fradley
Michael Fradley
JFJessica M. Frakes
Jessica M. Frakes
FKFarina Klocksieben
Farina Klocksieben
JPJose Mario Pimiento
Jose Mario Pimiento
Background: The incidence of esophageal cancer (EC) is increasing in the USA. Neoadjuvant therapy for locally advanced cancers followed by surgical resection is the standard of care. The most common post-esophagectomy cardiac complication is atrial fibrillation (AF). New-onset postoperative AF can require a prolonged hospital stay and may confer an overall poorer prognosis. In this study, we seek to identify clinical factors associated with postoperative AF. Methods: Query of an IRB approved database of 1,039 esophagectomies at our institution revealed 677 patients with EC from 1999 to 2017 who underwent esophagectomy after neoadjuvant treatment. Age, treatment location (primary vs. other), gender, neoadjuvant radiation type [2D vs. 3D vs. intensity modulated radiation therapy (IMRT)], radiation dose, surgery type (transthoracic vs. transhiatal vs. three field), smoking history, coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), operative time, blood transfusions, fluid management, and length of stay (LOS) were analyzed in relationship to the development of AF. Statistical analysis was performed with SPSS 24. Results: The mean age of the entire cohort was 64.3 (range, 28–86 years), with a Caucasian and male preponderance (White: 94.5%; male: 83.6%). Of the 677 patients, 14.9% (n=101) developed postoperative AF. Increasing age (P<0.001), increased radiation dose (P=0.034), operative time (P=0.001), and blood transfusions (P=0.027) were associated with AF. LOS was longer in patients with AF than those without AF (10.5 vs. 10.0 days, P=0.001). On multivariate analysis, increasing age (95% CI: 1.023–1.080, P<0.001) and radiation dose (95% CI: 1.000–1.001, P=0.034) remained significant. None of the other parameters assessed were associated with the development of AF. Conclusions: Increasing age and radiation dose were associated with the development of postoperative AF in this cohort. This study suggests that older patients or patients receiving higher radiation dose should be monitored more closely in the postoperative setting and potentially referred earlier preoperatively for cardio-oncology assessment. Future study is required to determine if modification of current radiation techniques and cardiac dose constraints in this patient population may be warranted.